| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ester Piovesana, Claudia Magrin, Matteo Ciccaldo, Martina Sola, Manolo Bellotto, Maurizio Molinari, Stéphanie Papin, Paolo Paganett. Tau accumulation in degradative organelles is associated to lysosomal stress. Scientific reports. vol 13. issue 1. 2023-10-21. PMID:37865674. |
considering the presence of tau lesions in parkinson's disease as well as in multiple neurodegenerative disorders including alzheimer's disease, our data call for further studies on strategies to alleviate alp dysfunction as new therapeutic opportunity for neurodegenerative diseases and lsd. |
2023-10-21 |
2023-11-08 |
human |
| Carolyn Tallon, Benjamin J Bell, Medhinee M Malvankar, Pragney Deme, Carlos Nogueras-Ortiz, Erden Eren, Ajit G Thomas, Kristen R Hollinger, Arindom Pal, Maja Mustapic, Meixiang Huang, Kaleem Coleman, Tawnjerae R Joe, Rana Rais, Norman J Haughey, Dimitrios Kapogiannis, Barbara S Slushe. Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in murine Alzheimer's disease. Research square. 2023-10-20. PMID:37502930. |
cognitive decline in alzheimer's disease (ad) is associated with prion-like tau propagation between neurons along synaptically connected networks, in part via extracellular vesicles (ev). |
2023-10-20 |
2023-11-08 |
Not clear |
| Kayo Yukawa, Satomi Yamamoto-Mcguire, Louis Cafaro, Christine Hong, Fredrik Kamme, Tsuneya Ikezu, Seiko Ikez. Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice. Acta neuropathologica communications. vol 11. issue 1. 2023-10-20. PMID:37853497. |
tau tubulin kinase-1 (ttbk1), a neuron-specific tau kinase, is highly expressed in the entorhinal cortex and hippocampal regions, where early tau pathology evolves in alzheimer's disease (ad). |
2023-10-20 |
2023-11-08 |
mouse |
| Jenat Pazheparambil Jerom, Soorylekshmi Madhukumar, Raveendran Harikumaran Nair, Sunilkumar Puthenpurackal Narayana. Anti-amyloid potential of some phytochemicals against Aβ-peptide and α-synuclein, tau, prion, and Huntington proteins. Drug discovery today. 2023-10-20. PMID:37858630. |
examples include the self-assembly of phenylalanine, which causes phenylketonuria; aβ, which causes alzheimer's disease; the tau protein, which causes both alzheimer's and parkinson's diseases; and α-synuclein, which causes parkinson's illness. |
2023-10-20 |
2023-11-08 |
Not clear |
| Fernando Gonzalez-Ortiz, Thomas K Karikari, Giuseppe Mario Bentivenga, Simone Baiardi, Angela Mammana, Michael Turton, Przemysław R Kac, Andrea Mastrangelo, Peter Harrison, Sabina Capellari, Henrik Zetterberg, Kaj Blennow, Piero Parch. Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2023-10-20. PMID:37858957. |
levels of plasma brain-derived tau and p-tau181 in alzheimer's disease and rapidly progressive dementias. |
2023-10-20 |
2023-11-08 |
Not clear |
| Sumit Da. Alzheimer's Type Neuropathological Changes in a Patient with Depression and Anxiety: A Case Report and Literature Review of Neuropathological Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. Case reports in neurological medicine. vol 2023. 2023-10-20. PMID:37860076. |
postmortem examination of the brain revealed severe alzheimer's type neuropathological changes, which included significant tau and beta-amyloid pathology in limbic regions, which were thought to represent correlates of the patient's depression and anxiety. |
2023-10-20 |
2023-11-08 |
Not clear |
| Julia Telser, Kirsten Grossmann, Niklas Wohlwend, Lorenz Risch, Christoph H Saely, Philipp Werne. Phosphorylated tau in Alzheimer's disease. Advances in clinical chemistry. vol 116. 2023-10-20. PMID:37852722. |
phosphorylated tau in alzheimer's disease. |
2023-10-20 |
2023-11-08 |
Not clear |
| Himanshi Singh, Asmita Das, Mohammad Moshahid Khan, Tayebeh Pourmotabbe. New insights into the therapeutic approaches for the treatment of tauopathies. Neural regeneration research. vol 19. issue 5. 2023-10-20. PMID:37862204. |
tauopathies are a group of neurological disorders, including alzheimer's disease and frontotemporal dementia, which involve progressive neurodegeneration, cognitive deficits, and aberrant tau protein accumulation. |
2023-10-20 |
2023-11-08 |
Not clear |
| Nicole Koutsodendris, Jessica Blumenfeld, Ayushi Agrawal, Michela Traglia, Oscar Yip, Antara Rao, Min Joo Kim, Maxine R Nelson, Yung-Hua Wang, Brian Grone, Yanxia Hao, Reuben Thomas, Misha Zilberter, Seo Yeon Yoon, Patrick Arriola, Yadong Huan. APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release. Cell reports. 2023-10-20. PMID:37863057. |
apolipoprotein e4 (apoe4) is an important driver of tau pathology, gliosis, and degeneration in alzheimer's disease (ad). |
2023-10-20 |
2023-11-08 |
mouse |
| Andrea Elia, Rebecca Parodi-Rullan, Rafael Vazquez-Torres, Ashley Carey, Sabzali Javadov, Silvia Fossat. Amyloid β induces cardiac dysfunction and neuro-signaling impairment in the heart of an Alzheimer's disease model. bioRxiv : the preprint server for biology. 2023-10-19. PMID:37502936. |
alzheimer's disease (ad) is a complex neurodegenerative disorder characterized by cerebral amyloid β (aβ) deposition and tau pathology. |
2023-10-19 |
2023-11-08 |
mouse |
| Rigina L Gallagher, Rebecca Langhough Koscik, Jason F Moody, Nicholas M Vogt, Nagesh Adluru, Steven R Kecskemeti, Carol A Van Hulle, Nathaniel A Chin, Sanjay Asthana, Gwendlyn Kollmorgen, Ivonne Suridjan, Cynthia M Carlsson, Sterling C Johnson, Douglas C Dean, Henrik Zetterberg, Kaj Blennow, Andrew L Alexander, Barbara B Bendli. Neuroimaging of tissue microstructure as a marker of neurodegeneration in the AT(N) framework: defining abnormal neurodegeneration and improving prediction of clinical status. Alzheimer's research & therapy. vol 15. issue 1. 2023-10-18. PMID:37848950. |
alzheimer's disease involves accumulating amyloid (a) and tau (t) pathology, and progressive neurodegeneration (n), leading to the development of the ad clinical syndrome. |
2023-10-18 |
2023-11-08 |
Not clear |
| Brian A Willis, Albert C Lo, Jeffrey L Dage, Sergey Shcherbinin, Louise Chinchen, Scott W Andersen, Elizabeth S LaBell, David G S Perahia, Paula M Hauck, Stephen L Low. Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial. Journal of Alzheimer's disease reports. vol 7. issue 1. 2023-10-18. PMID:37849628. |
zagotenemab (ly3303560), a monoclonal antibody, preferentially binds to extracellular, misfolded, aggregated tau that has been implicated in alzheimer's disease (ad). |
2023-10-18 |
2023-11-08 |
human |
| Ishnoor Kaur, Tapan Behl, G Sundararajan, P Panneerselvam, A R Vijayakumar, G P Senthilkumar, T Venkatachalam, Dharmender Jaglan, Shivam Yadav, Khalid Anwer, Neeraj Kumar Fuloria, Aayush Sehgal, Monica Gulati, Sridevi Chigurupat. BIN1 in the Pursuit of Ousting the Alzheimer's Reign: Impact on Amyloid and Tau Neuropathology. Neurotoxicity research. 2023-10-17. PMID:37847429. |
bin1 in the pursuit of ousting the alzheimer's reign: impact on amyloid and tau neuropathology. |
2023-10-17 |
2023-11-08 |
Not clear |
| Ishnoor Kaur, Tapan Behl, G Sundararajan, P Panneerselvam, A R Vijayakumar, G P Senthilkumar, T Venkatachalam, Dharmender Jaglan, Shivam Yadav, Khalid Anwer, Neeraj Kumar Fuloria, Aayush Sehgal, Monica Gulati, Sridevi Chigurupat. BIN1 in the Pursuit of Ousting the Alzheimer's Reign: Impact on Amyloid and Tau Neuropathology. Neurotoxicity research. 2023-10-17. PMID:37847429. |
belonging to the bin1/amphiphysin/rvs167 (bar) superfamily, the bridging integrator (bin1) has been identified to impact two major pathological hallmarks in alzheimer's disease (ad), i.e., amyloid beta (aβ) and tau accumulation. |
2023-10-17 |
2023-11-08 |
Not clear |
| Mingyue Jin, Shengming Wang, Xiaodie Gao, Zhenyou Zou, Shinji Hirotsune, Liyuan Su. Pathological and physiological functional cross-talks of α-synuclein and tau in the central nervous system. Neural regeneration research. vol 19. issue 4. 2023-10-16. PMID:37843221. |
previous works have revealed that intracellular deposition of α-synuclein and/or tau causes many neurodegenerative disorders, including alzheimer's disease and parkinson's disease. |
2023-10-16 |
2023-11-08 |
mouse |
| Bingge Zhang, Huali Wan, Maimaitijian Maierwufu, Qian Liu, Ting Li, Ye He, Xin Wang, Gongping Liu, Xiaoyue Hong, Qiong Fen. STAT3 ameliorates truncated tau-induced cognitive deficits. Neural regeneration research. vol 19. issue 4. 2023-10-16. PMID:37843229. |
proteolytic cleavage of tau by asparagine endopeptidase (aep) creates tau-n368 fragments, which may drive the pathophysiology associated with synaptic dysfunction and memory deterioration in the brain of alzheimer's disease patients. |
2023-10-16 |
2023-11-08 |
mouse |
| Swathi Suresh, Chitra Vellapandia. Cyanidin Ameliorates Bisphenol A-Induced Alzheimer's Disease Pathology by Restoring Wnt/β-Catenin Signaling Cascade: an In Vitro Study. Molecular neurobiology. 2023-10-16. PMID:37843801. |
alzheimer's disease (ad) is a progressive neurodegenerative disorder causing memory loss and cognitive decline, linked to amyloid-beta (aβ) plaques and hyperphosphorylated tau protein accumulation in the brain. |
2023-10-16 |
2023-11-08 |
Not clear |
| Benjamin H Rajewski, Kamlesh M Makwana, Isaac J Angera, Danielle K Geremia, Anna R Zepeda, Grace I Hallinan, Ruben Vidal, Bernardino Ghetti, Arnaldo L Serrano, Juan R Del Vall. β-Bracelets: Macrocyclic Cross-β Epitope Mimics Based on a Tau Conformational Strain. Journal of the American Chemical Society. 2023-10-16. PMID:37844142. |
the aggregation of misfolded tau into neurotoxic fibrils is linked to the progression of alzheimer's disease (ad) and related tauopathies. |
2023-10-16 |
2023-11-08 |
Not clear |
| Chenxi He, Jinying Gu, Danni Wang, Keran Wang, Yuxuan Wang, Qidong You, Lei Wan. Small molecules targeting molecular chaperones for tau regulation: Achievements and challenges. European journal of medicinal chemistry. vol 261. 2023-10-15. PMID:37839344. |
abnormal post-translational modification of microtubule-associated protein tau (mapt) is a prominent pathological feature in alzheimer's disease (ad). |
2023-10-15 |
2023-11-08 |
Not clear |
| Kuang-Wei Wang, Gary Zhang, Min-Hao Ku. Frontotemporal Dementia P301L Mutation Potentiates but Is Not Sufficient to Cause the Formation of Cytotoxic Fibrils of Tau. International journal of molecular sciences. vol 24. issue 19. 2023-10-14. PMID:37834443. |
understanding the conditions and mechanisms whereby selective mutations aggravate the pathogenic activities of tau can provide pivotal clues on novel strategies for drug development for frontotemporal dementia and other related neurodegenerative tauopathies, including alzheimer's disease. |
2023-10-14 |
2023-10-15 |
Not clear |